Data from Gundersen Health System, La Crosse, Wis, has externally verified the clinical significance of GeneStrat and VeriStrat blood-based testing for patients with non-small cell lung cancer (NSCLC).1

“These study results demonstrated the value of the Biodesix lung reflex testing strategy at the time of initial diagnosis of lung cancer,” says Jennifer Mattingley, MD, of Gundersen Health System. “Expediting treatment decisions and having informed prognostic conversations with patients can decrease the time between diagnosis and treatment and offer an improved patient experience for lung cancer patients.”

To evaluate the utility of the Biodesix lung reflex testing strategy, GeneStrat results were compared to tissue-based mutation results, and VeriStrat outcome analysis included assessment of its ability to stratify newly diagnosed lung cancer patients, according to progression-free survival (PFS) and overall survival (OS). All results for blood-based testing were available in less than 72 hours, with an average turnaround time of 24.1 hours. GeneStrat genomic testing was highly accurate (93% sensitivity, 99% specificity) and 96% concordant with tissue-based mutation results. VeriStrat proteomic testing was prognostic for PFS and OS across all stages of lung cancer. Patients with VeriStrat-good and VeriStrat-poor status had significantly different PFS and OS.

Biodesix’s VeriStrat test is a predictive and prognostic blood-based proteomic test for patients with NSCLC. The test is used to assess disease aggressiveness by characterizing host response to the tumor, classifying patients as either VeriStrat-good or VeriStrat-poor. The test has been shown to be predictive for EGFR targeted agents after progression on platinum based chemotherapy.2 The GeneStrat test is a blood-based genomic mutation test that can inform the use of targeted therapies (EGFR T790M, EML4-ALK, KRAS, BRAF). Both VeriStrat and GeneStrat blood-based tests offer results to ordering physicians within 72 hours.

For more information, visit Biodesix.


  1. Mattingley J and Oettel K. Blood-based genomic and proteomic testing for newly diagnosed lung cancer patients to facilitate rapid treatment decisions and prognostic conversations. Poster presented at the 2016 annual Chest meeting (Los Angeles: American College of Chest Physicians, 22–26 October 2016). Available at:
  1. Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomized phase 3 trial. Lancet Oncol. 2014;15(7):713–721; doi: